MX2019011891A - Proteinas derivadas de clpb y usos de las mismas. - Google Patents

Proteinas derivadas de clpb y usos de las mismas.

Info

Publication number
MX2019011891A
MX2019011891A MX2019011891A MX2019011891A MX2019011891A MX 2019011891 A MX2019011891 A MX 2019011891A MX 2019011891 A MX2019011891 A MX 2019011891A MX 2019011891 A MX2019011891 A MX 2019011891A MX 2019011891 A MX2019011891 A MX 2019011891A
Authority
MX
Mexico
Prior art keywords
relates
present
clpb
proteins derived
reducing
Prior art date
Application number
MX2019011891A
Other languages
English (en)
Inventor
Serguei Fetissov
Grégory Lambert
Romain Legrand
Nicolas Lucas
Original Assignee
Targedys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targedys filed Critical Targedys
Publication of MX2019011891A publication Critical patent/MX2019011891A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a polipéptidos y proteínas que comprenden un fragmento de una proteína ClpB y a composiciones a partir de los mismos. La presente invención también se refiere 5 al tratamiento y/o prevención de la inflamación, en particular a enfermedades y trastornos relacionados con el sobrepeso y/o la obesidad. La presente invención también se refiere a métodos para inducir la saciedad, prolongar la saciedad, reducir el tamaño del alimento, reducir la ingesta de alimentos, controlar el aumento de peso y estimular la pérdida de peso.
MX2019011891A 2017-04-03 2018-04-03 Proteinas derivadas de clpb y usos de las mismas. MX2019011891A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305400.8A EP3385276A1 (en) 2017-04-03 2017-04-03 Proteins derived from clpb and uses thereof
PCT/EP2018/058451 WO2018185080A1 (en) 2017-04-03 2018-04-03 Proteins derived from clpb and uses thereof

Publications (1)

Publication Number Publication Date
MX2019011891A true MX2019011891A (es) 2020-07-27

Family

ID=58632306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011891A MX2019011891A (es) 2017-04-03 2018-04-03 Proteinas derivadas de clpb y usos de las mismas.

Country Status (12)

Country Link
US (1) US20200131495A1 (es)
EP (2) EP3385276A1 (es)
JP (1) JP2020515647A (es)
KR (1) KR20200010209A (es)
CN (1) CN111108114A (es)
AU (1) AU2018247816A1 (es)
BR (1) BR112019020779A2 (es)
CA (1) CA3058816A1 (es)
IL (1) IL269751A (es)
MX (1) MX2019011891A (es)
RU (1) RU2019135294A (es)
WO (1) WO2018185080A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886882A1 (en) 2018-11-28 2021-10-06 Targedys Hafnia alvei formulations
CN114525252B (zh) * 2022-03-10 2023-12-01 广州源井生物科技有限公司 一种提高mda-mb-231单细胞克隆形成率的单克隆增强培养基与培养方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
IL122432A (en) 1995-06-07 2000-07-16 Cygnus Therapeutic Systems Transdermal patch for preventing ovulation
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
ES2325773T5 (es) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US20160339094A1 (en) * 2013-12-05 2016-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Bacterial influence of host feeding and emotion via clpb protein mimicry of a-msh
EP3076985A1 (en) * 2013-12-05 2016-10-12 Institut National de la Santé et de la Recherche Médicale Bacterial influence on regulation of appetite via clpb protein mimicry of alpha-msh

Also Published As

Publication number Publication date
AU2018247816A1 (en) 2019-10-24
WO2018185080A1 (en) 2018-10-11
RU2019135294A (ru) 2021-05-05
CN111108114A (zh) 2020-05-05
BR112019020779A2 (pt) 2020-04-28
US20200131495A1 (en) 2020-04-30
JP2020515647A (ja) 2020-05-28
IL269751A (en) 2019-11-28
CA3058816A1 (en) 2018-10-11
EP3606943A1 (en) 2020-02-12
EP3385276A1 (en) 2018-10-10
KR20200010209A (ko) 2020-01-30

Similar Documents

Publication Publication Date Title
JO3745B1 (ar) ناهضات بروتينات رابطة لل icos
MY182667A (en) Food compositions comprising one or both of recombinant beta-lactoglobulin protein and recombinant alphalactalbumin protein
JP2014518542A5 (es)
WO2011070214A8 (es) Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral
MX2018003411A (es) Terapia glucodirigida.
MX2023008211A (es) Composiciones y metodos para disminuir la expresion de tau.
RU2017142932A (ru) Фармацевтические и пищевые композиции для индуцирования насыщения и продления сытости у нуждающихся в этом субъектов
MX2019011891A (es) Proteinas derivadas de clpb y usos de las mismas.
PH12018500098A1 (en) Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
MX2021009035A (es) Composiciones y metodos para producir productos alimenticios con proteina animal recombinante.
MX2020009736A (es) Composiciones que comprenden cepas bacterianas.
WO2019045287A3 (ko) 찔레열매 추출물의 분획물을 유효성분으로 포함하는 면역 질환의 예방, 개선 또는 치료용 조성물
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.
PH12021550488A1 (en) Thermally treated composition comprising plant proteins and methods of production and use thereof
WO2012019086A3 (en) Inhibition of lar phosphatase to enhance therapeutic angiogenesis
WO2019081595A3 (en) Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
EP4061403A4 (en) SECRETABLE PROTEIN-INDUCED IMMUNE TOLERANCE AND TREATMENT OF AUTOIMMUNE, ALLERGIC AND OTHER DISEASES AND DISORDERS
PH12017500743A1 (en) Tau protein production accelerator, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by tau protein deficiency
EP3762005A4 (en) SYNERGIC HERBAL COMPOSITIONS FOR THE TREATMENT OF OBESITY AND OVERWEIGHT
AU2017247612A9 (en) Hafnia alvei based pharmaceutical and food compositions for inducing satiation and prolonging satiety
MX2018007212A (es) Peptidos dieteticos.
MX371444B (es) Metodo para inducir saciedad.
MX2022014158A (es) Metodos que reducen los antojos de alimentos, promueven la perdida de peso y/o tratan el sobrepeso o la obesidad.